breast cancer
Conditions
Interventions
Test group:Eribulin combined with initumab combined with pyrotinib
Sponsors
Fifth Affiliated Hospital, Sun Yat-Sen University
Eligibility
Sex/Gender
Female
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. 18 years old =55 %; 8. Adequate bone marrow functional reserve: white blood cell count >=3.0×10^9/L, neutrophil count >=1.5×10^9/L; platelet count >=100×10^9/L; hemoglobin >=90g/L; 9. AST and ALT <= 2 times the upper limit of normal value, alkaline phosphatase <= 2 times the upper limit of normal value, total bilirubin <= 2 times the upper limit of normal value; serum creatinine <= 1.5 times the upper limit of normal value; 10. For female patients who are not menopausal or surgically sterilized: consent to contraception during treatment and for at least 7 months after the last dose of study treatment; 11. Voluntarily join this study, sign informed consent, have good compliance and be willing to cooperate with follow-up.
Exclusion criteria
Exclusion criteria: 1. Her-2 or hormone receptor status is unknown; 2. Patients with known allergies to the active ingredient or other components of the study drug; 3. It is judged by the researcher that other anti-tumor treatments are needed during treatment. 4. Those with severe heart disease or discomfort who are expected to be unable to tolerate chemotherapy, including but not limited to: A. Fatal arrhythmia or higher-grade atrioventricular block (second-degree type 2 atrioventricular block or third-degree atrioventricular block); B. Unstable angina; C. Clinically significant valvular heart disease; D. Electrocardiogram showing transmural myocardial infarction; E. Uncontrollable hypertension. 5. Have undergone major surgical operations unrelated to breast cancer within 4 weeks before enrollment, or the patient has not fully recovered from such surgical operations; 6. Serious or uncontrolled infections that may affect study treatment or evaluation of study results, including but not limited to active hepatitis virus infection, human immunodeficiency virus (HIV) antibody positivity, lung infection, etc.; 7. Have a history of other malignant tumors in the past 5 years (except for cured cervical carcinoma in situ or cutaneous basal cell carcinoma, etc.); 8. People with basic gastrointestinal diseases (especially a history of long-term diarrhea and constipation), inability to swallow, intestinal obstruction, or other factors that affect drug taking and absorption; 9. The investigator believes that the patient has any other condition that makes him/her unfit to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-Free Survival;Safety evaluation;Overall Survival; | — |
Countries
China
Contacts
Public ContactPeng Peijian
Fifth Affiliated Hospital, Sun Yat-Sen University
Outcome results
None listed